New triple therapy targets stubborn lung cancer in early trial
NCT ID NCT07113691
First seen Nov 06, 2025 · Last updated Jun 08, 2026 · Updated 34 times
Summary
This early-phase study is for people with extensive-stage small-cell lung cancer whose disease persists, returns, or progresses after initial chemotherapy. Researchers are testing whether adding an experimental drug (iadademstat) to standard radiation and immunotherapy (atezolizumab) is safe and tolerable. About 15 participants will receive the combination to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.